Pathogenetically justified use in real clinical practice of vaginal estriol 0.5 mg in women of different ages

Research in recent decades has shown a steady increase in the average life expectancy of humans, and women in particular. Any epithelial tissue reacts to changes in the surrounding hormonal environment in a similar way, but none of them can compare with the epithelium of the vaginal vault and cervix in terms of the speed and clarity of reaction to hormones, primarily sex steroids. The urogenital tract is especially sensitive to a decrease in estrogen levels, and about half of all women, both in reproductive age and during hormonal changes, may experience symptoms associated with vulvovaginal atrophy, affecting sexual health and quality of life. Estriol is the main estrogen that specifically addresses problems caused by estrogen deficiency: dyspareunia, dryness and itching in the vagina and lower genitourinary tract, urinary disorders, moderate urinary incontinence, as well as recurrent vulvovaginitis and cystitis. According to international and Russian clinical guidelines, the prescription of 0.5 mg is pathogenetically justified with a high level of persuasiveness and reliability. Vulvovaginal dystrophy in women of different ages is a multidisciplinary problem at the intersection of gynecology, urology and dermatology, which can and should be solved to prevent more severe gynecological and urological pathologies.

1. Calleja-Agius J, Brincat MP. Urogenital atrophy. Climacteric. 2009;12(4):279–285. doi: https://doi.org/10.1080/13697130902814751

2. Panay N, Palacios S, Bruyniks N, Particco M, Nappi RE. Symptom severity and quality of life in the management of vulvovaginal atrophy in postmenopausal women. Maturitas. 2019. doi: https://doi.org/10.1016/j.maturitas.2019.03.013

3. Palacios S, Nappi RE, Bruyniks N, et al. The European Vulvovaginal Epidemiological Survey (EVES): prevalence, symptoms and impact of vulvovaginal atrophy of menopause. Climacteric J Int Menopause Soc. 2018;21(3):286–291

4. Andreeva EN, Sheremetyeva EV. The role of estriol in the treatment of atrophy of the mucous membrane of the lower genitourinary tract in postmenopausal women. Problems of Endocrinology. 2022;68(6):157-163. (In Russ.). doi: https://doi.org/10.14341/probl13198

5. Аполихина И.А., Горбунова Е.А. Клинико-морфологические аспекты вульвовагинальной атрофии. Медицинский cовет. 2014; 9: 110-7.

6. Bleibel B, Nguyen H. Vaginal Atrophy. 2023 Jul 3. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan.

7. Crandall CJ. Treatment of Vulvovaginal Atrophy. JAMA. 2019;322(19):1910-1911. doi: https://doi.org/10.1001/jama.2019.15100

8. Klinicheskie rekomendacii, proekt, Amenoreya i olinomenoreya, 2024, MZ RF (In Russ.). https://roag-portal.ru/projects_gynecology

9. Klinicheskie rekomendacii. Menopauza i klimaktericheskoe sostoyanie u zhenshchin, . — Moskva, 2021. (In Russ.).

10. Registr lekarstvennyh sredstv Rossii (In Russ.). https://www.rlsnet.ru/drugs/ovestin-67#sposob-primeneniia-i-dozy

11. Angelou K, Grigoriadis T, Diakosavvas M, Zacharakis D, Athanasiou S. The Genitourinary Syndrome of Menopause: An Overview of the Recent Data. Cureus. 2020;12(4):e7586. doi: https://doi.org/10.7759/cureus.7586

12. The NAMS 2020 GSM Position Statement Editorial Panel. The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society. Menopause. 2020;27(9):976-992. doi: https://doi.org/10.1097/GME.0000000000001609

13. Apolihina IA, Yureneva SV, Malyshkina DA. Genitourinarnyj menopauzal’nyj sindrom: sovremennye podhody k diagnostike i lecheniyu. Akusherstvo i ginekologiya. 2020;12:4-8 (In Russ.).

14. Khan IU, Serra CA, Anton N, Er-Rafik M, Blanck C, et al. Microfluidic conceived Trojan microcarriers for oral delivery of nanoparticles. Int J Pharm. 2015;493(1-2):7-15. doi: https://doi.org/10.1016/j.ijpharm.2015.06.028

15. Anton N, Jakhmola A, Vandamme TF. Trojan microparticles for drug delivery. Pharmaceutics. 2012;4(1):1-25. doi: https://doi.org/10.3390/pharmaceutics4010001

16. Li X, Anton N, Ta TM, Zhao M, Messaddeq N, Vandamme TF. Microencapsulation of nanoemulsions: novel Trojan particles for bioactive lipid molecule delivery. Int J Nanomedicine. 2011;6:1313-1325. doi: https://doi.org/10.2147/IJN.S20353

17. Comini ACM, Carvalho BM, Moreira MJB, Reis PCA, Colapietro L, et al. Safety and Serum Estradiol Levels in Hormonal Treatments for Vulvovaginal Atrophy in Breast Cancer Survivors: A Systematic Review and Meta-Analysis. Clin Breast Cancer. 2023;23(8):835-846. doi: https://doi.org/10.1016/j.clbc.2023.08.003

18. Lázaro-Carrasco de la Fuente J, Cuerva González M, González Rodríguez S, Delgado Marín JL, Cuevas Castillo C, Nieto Magro C. Early Effect of 0.005% Estriol Vaginal Gel on Symptoms and Signs of Vulvovaginal Atrophy. J Menopausal Med. 2022;28(2):60-69. doi: https://doi.org/10.6118/jmm.21038

19. Nederzhanie mochi u vzroslyh. Klinicheskie rekomendacii. — MZ RF. — Moskva, 2024 (In Russ.).

20. Labrie F, Martel C, Pelletier G. Is vulvovaginal atrophy due to a lack of both estrogens and androgens? Menopause (New York, NY). 2017;24(4):452–461

21. Vetuschi A, D’Alfonso A, Sferra R, et al. Changes in muscularis propria of anterior vaginal wall in women with pelvic organ prolapse. Eur J Histochem. 2016;60(1):33-38

22. Donders GGG, Ruban K, Bellen G, Grinceviciene S. Pharmacotherapy for the treatment of vaginal atrophy. Expert Opin Pharmacother. 2019;20(7):821-835. doi: https://doi.org/10.1080/14656566.2019.1574752

23. Vzaimozamenyaemye lekarstvennye preparaty (p. 4 ch. 4 st. 3 Federal’nogo zakona ot 27.12.2019 № 475-FZ, p. 8 postanovleniya Pravitel’stva ot 05.09.2020 № 1360) (In Russ.).

24. Nederzhanie mochi. Klinicheskie rekomendacii. — MZ RF. — Moskva, 2020 (In Russ.).

25. Klinicheskie rekomendacii. Menopauza i klimaktericheskoe sostoyanie u zhenshchin, . — Moskva, 2024. (In Russ.).

26. Islam RM, Bell RJ, Green S, Page MJ, Davis SR. Safety and efficacy of testosterone for women: a systematic review and meta-analysis of randomised controlled trial data. Lancet Diabetes Endocrinol. 2019;7(10):754-766. doi: https://doi.org/10.1016/S2213-8587(19)30189-5

27. Lethaby A, Ayeleke RO, Roberts H. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev. 2016;2016(11). doi: https://doi.org/10.1002/14651858.CD001500.pub3

28. Rueda C, Osorio AM, Avellaneda AC, Pinzón CE, Restrepo OI. The efficacy and safety of estriol to treat vulvovaginal atrophy in postmenopausal women: a systematic literature review. Climacteric. 2017. doi: https://doi.org/10.1080/13697137.2017.1329291

29. Hirschberg AL, Bitzer J, Cano A, et al. Topical estrogens and non-hormonal preparations for postmenopausal vulvovaginal atrophy: An EMAS clinical guide. Maturitas. 2021;148:55-61. doi: https://doi.org/10.1016/j.maturitas.2021.04.005

30. Crandall CJ, Diamant A, Santoro N. Safety of vaginal estrogens: a systematic review. Menopause. 2020;27(3):339-360. doi: https://doi.org/10.1097/GME.0000000000001468

31. Shlyakhto EV, Sukhikh GT, Serov VN, Dedov II, Arutyunov GP, et al. Russian eligibility criteria prescribing menopausal hormonal hormones therapy for patients with cardiovascular and metabolic diseases. Consensus document of the Russian Cardiological Society, Russian Society of Obstetricians and Gynecologists, Russian Association of Endocrinologists, Eurasian Association of Therapists, Association of Phlebologists of Russia. Problems of Endocrinology. 2023;69(5):115-136. (In Russ.). doi: https://doi.org/10.14341/probl13394